الفهرس 
Influence of cyp3a5 gene polymorphism on cyclosporine dosage in kidney transplant recipients
AbstractOnly 14 pages are availabe for public view
 |  | from | 150 |  |  |
| | | from | 150 | | |
Abstract
Renal transplantation is currently the treatment of choice for end-stage renal disease (ESRD). The complications of the renal transplantation are rejection, nephrotoxicity of calcineurin inhibitors (CNI), and recurrence of native kidney disease. Cyclosporine (CsA) is a member of CNI family, which is widely used as a basic component of immunosuppressive regimens to prevent allograft rejection in solid organ transplantation. CYP3A4, and CYP3A5 are the main genes involved in the pharmacokinetics of CNI. Several single nucleotide polymorphisms were identified in these genes such as CYP3A5 (6986A > G). Aim of the work: To assess the impact of CYP3A5 (6986A > G) SNP on the dose and blood level of CsA among Egyptian renal transplant recipients after three months of transplantation. Subjects and methods: A total of 50 renal transplant recipients receiving CsA subjected to genotyping analysis of CYP3A5 (6986A > G) by Real-time PCR using the TaqMan SNP genotyping assay. The C0 and C2 of CsA were measured and their relationships with CYP3A5 genotypes were assessed